Clinical Trial Search

Primary: Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT Images — 0.851; 0.865; 0.919 ratio

Primary: Number of Subjects Reporting Any Adverse Events — 97 Participants

Primary: 1. Safety and Tolerability of Universal Donor FMT Compared to Placebo: FMT-related Adverse Events Grade 2 or Above — 4; 0 Participants

Primary: Proportion of Participants Who Had Recurrent Systemic Allergic Reaction to Vaccine — 0.125 Proportion of participants

Primary: Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+ — 8.3 percentage of positively stained cells

Primary: Change in Percentage of Participants With HIV Transmission Risk at Month 6 — 23.077; 38.462; 46.154; 46.154 percentage of participants with no risk — p=.19

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…

Primary: Mean Number of Days Device Was Used — 38.0; 38.4 Days

Primary: Recommended Phase 2 Dose of LY3022855 Combined With Durvalumab (Maximum Tolerated Dose [MTD]) — 100 milligrams (mg)

Primary: HbA1c Level at 24 Weeks — 62.8; 67.7 mmol/mol

Primary: Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308 — 7.1; 25.0 Percentage of participants

Primary: Knee Society Scores — 92.9 units on a scale

Primary: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) — 0 Percentage of participants

Primary: Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) — 1055; 840; 885; 185 Participants

Primary: Inferior Corneal Staining Score — -0.08; -0.03 units on a scale